ABSTRACT
Objective:
To investigate the clinical effect of dapagliflozin combined with
metformin on
type 2 diabetes mellitus (T2DM).
Methods:
A total of 100
patients with T2DM
who received
treatment in The Second People's
Hospital of Hefei from June 2019 to May 2021 were included in this study. They were randomly divided into a
control group ( n = 50) and an experimental group ( n = 50). The
control group was treated with
metformin, and the experimental group was treated with dagglitazin combined with
metformin. All
patients were treated for 3 months.
Blood glucose index,
blood lipid level, and the
incidence of adverse reactions were compared between the two groups.
Results:
After treatment,
fasting blood glucose, 2-hour post-prandial
blood glucose, and
glycosylated hemoglobin in the experimental group were (5.56 ± 0.37) mmol/L, (8.32 ± 0.23) mmol/L, and (6.17 ± 0.26)% respectively, which were significantly lower than (6.96 ± 0.48) mmol/L, (9.58 ± 0.39) mmol/L, and (7.27 ± 0.26)% respectively in the
control group ( t = 3.59, 6.92, 5.03, all P < 0.05). The total
cholesterol and
triglyceride in the experimental group were (3.58 ± 0.53) mmol/L and (1.25±0.26) mmol/L, respectively, which were significantly lower than (4.94 ± 0.58) mmol/L and (1.93 ± 0.18) mmol/L in the
control group ( t = 3.16, 4.25, both P < 0.05). There was no significant difference in the
incidence of adverse reactions between the two groups ( P > 0.05).
Conclusion:
Dapagliflozin combined with
metformin can effectively control
blood glucose and
blood lipid in T2DM
patients without increasing adverse reactions.